Pipeline Alert: Jocasta Neuroscience $35M Series A
Just triggered: Jocasta Neuroscience’s $35M Series A. CEO Albert Agro is in market for CRO & eClinical. Fuel your pipeline with our battle card. Plan your next touch and close fast.
Published on
Do not index
Do not index
🚀 Battle Card: Jocasta Neuroscience
Quick trigger:
👤 Decision Maker in the News
- Albert Agro, PhD, CEO 📧 aagro@jocastaneuro.com
💡 Why It Matters
- This Jocasta Neuroscience sales trigger signals a ramp in funding to push JN-0413 toward clinical trials for dementia patients. → Source
🎯 Core Pain Point
- Advancing a preclinical asset into regulatory-ready clinical trials
- Securing CRO partners and eClinical systems that scale
💰 What to Pitch
- Primary: End-to-end CRO services → Accelerate IND filing & trial kickoff
- Expansion: Cloud-based CTMS & eTMF → Ensure GCP compliance and real-time visibility
🗺️ Quick Context
- HQ: Scottsdale, AZ
- Employees: ≈ 50
- Rev: ≈ $0
- Website: jocastaneuro.com
Armed with the Jocasta Neuroscience sales trigger, you know they’re in market for trial partners.
🤼 Competitive Intel
Which other vendors you’ll probably face to win Jocasta Neuroscience’s business.
- Medidata — CTMS / EDC
- Unique edge: Deep analytics & patient-centric modules
- Evaluated by CEO & Head of R&D for data integrity
- Veeva Systems — CTMS / eTMF
- Unique edge: Built-in compliance workflows for life sciences
- Evaluated by VP Ops for seamless integration
- Oracle Health Sciences — CTMS / Clinical Operations
- Unique edge: Enterprise-grade scalability & global support
- Evaluated by CFO & Head of Clinical for budget predictability
✅ Do-Now Checklist
Connect with Albert Agro on email and mention the Jocasta Neuroscience sales trigger
Build a tailored intro referencing their $35M Series A and in-market needs
Schedule follow-ups in CRM (Day 3 & Day 10)
Next up: use this Jocasta Neuroscience sales trigger in your first touch to stand out.
Subscribe to NewsletterForLeads
🧠 Copy My Prompt for Personalized Cold Outreach
────────────────────────────
✏️ YOUR COMPANY
────────────────────────────
OUR_COMPANY = ❑❑
OFFER_BRIEF = ❑end-to-end CRO services to accelerate IND filing & trial kickoff❑
PROOF_METRIC = ❑30% faster IND submissions❑
CTA_STYLE = ❑quick_call❑
TONE = ❑friendly❑
────────────────────────────
📌 TARGET COMPANY
────────────────────────────
NAME = Albert
COMPANY = Jocasta Neuroscience
DEPT = Clinical Ops
SIZE = 3
BOTTLENECK = securing CRO partners that scale
EVENT = $35M Series A
DETAIL = their $35M Series A financing
PAIN = need to advance preclinical assets into regulatory-ready clinical trials
SRC = https://vcnewsdaily.com/jocasta-neuroscience/venture-capital-funding/lvjlydncsy
SIM_CO = Denali Therapeutics
WIN_METRIC = 30% faster IND submissions
NEXT_SIZE = 10
EMP_EST = ≈ 50
REV_EST = ≈ $0
────────────────────────
TASK FOR CHATGPT
────────────────────────
Role: “NewsletterForLeads SDR-Assist”.
Validate any ≈ guesses via SRC.
EMAIL (keep breaks):
Subject: 3-person Clinical Ops
Albert—noticed your Clinical Ops team is ≈ 3.
That’s when securing CRO partners that scale slows growth.
We helped Denali Therapeutics fix this with end-to-end CRO services to accelerate IND filing & trial kickoff.
Result: 30% faster IND submissions.
Quick call?
PS—next bottleneck hits ≈ 10.
DM ≤45 words, TONE:
Saw your post about their $35M Series A financing — need to advance preclinical assets into regulatory-ready clinical trials.
end-to-end CRO services to accelerate IND filing & trial kickoff. 30% faster IND submissions.
Quick chat?